Latest Structure Therapeutics News & Updates

See the latest news and media coverage for Structure. We track all announcements, press releases, and industry mentions in real time, all in one place.

Structure Therapeutics (Structure)

Clinical-stage biopharmaceutical company developing oral small molecule therapeutics

structuretx.com

Headquarters: South San Francisco, United States
Founded year: 2017
Company type: Public company
Number of employees: 50–300
Industry: Pharmaceuticals

Last updated Today

Latest news about Structure Therapeutics (Structure)

In short: Structure reported positive clinical trial results for its oral weight-loss drugs and secured funding for operations through 2028.

Company announcements

August 6 Structure

Structure Therapeutics reports second quarter 2026 results and highlights

First patients dosed in Phase 3 ACCOMPLISH program; John Berrios appointed CCO; $1.3 billion cash expected to fund operations through 2028.

June 17 Structure

Structure announces promising Phase 2b aleniglipron data

Data showed up to 16.2% weight loss, no plateau, and low discontinuation; Phase 3 on track for Q3 2026.

June 5 Structure

Structure has published aleniglipron trial data in Nature Medicine

The Phase 2b ACCESS study showed dose-dependent weight loss up to 16.2% at 56 weeks with low discontinuation, supporting Phase 3 initiation in Q3 2026.

May 7 Structure

Structure Therapeutics reports Q1 2026 financial results

Cash at $1.5B funds operations through 2028. Positive Phase 2 aleniglipron data with 16.3% weight loss. Phase 3 initiation on track for Q3 2026.

Media coverage

September 8 MSN

Structure Therapeutics advances weight-loss pills with new clinical data

Structure Therapeutics Inc. GPCR on Tuesday announced encouraging clinical trial findings for two of its main oral drug ...

September 8 Markets Insider

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target...

September 8 The Globe and Mail

Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

September 8 Seeking Alpha

Structure Therapeutics falls after trial data for lead obesity drugs

Structure Therapeutics (GPCR) stock slides in reaction to trial data for the company's lead obesity candidates, ACCG-2671 and aleniglipron. Read more here.

Never miss news about Structure

Track Structure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Structure competitors & trending companies

Browse news for competitors to Structure and other trending companies.